Diabetes drug could help heart failure patients with leaky valve

NCT ID NCT06027307

Ongoing Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether enavogliflozin, a diabetes drug, can improve outcomes in people with heart failure and a leaky tricuspid valve. About 541 participants will receive either the drug or a placebo for 18 months. Researchers will track heart-related events, valve worsening, and kidney function to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enavogliflozin (a diabetes drug that helps the heart and kidneys)
What this could lead to: If it works, this could offer a new treatment option for heart failure patients with a leaky tricuspid valve, potentially reducing hospitalizations and improving survival.
What could go wrong: This is a single phase 3 trial with 541 participants, so results may not apply to all patients. The drug may not show significant benefit over placebo, and side effects like dehydration or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION TRICUSPID REGURGITATION

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
Inha University Hospital

Incheon, South Korea
Samsung Medical Center

Seoul, South Korea
Seoul National University Hospital

Seoul, South Korea
Yonsei University Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.